Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
84 Results for "
Diabetic model
" in MedChemExpress (MCE) Product Catalog:
Products (84)
84 Results for "Diabetic model" in MCE Product Catalog:
Cat. No.: HY-170233
Research Areas:
NLRP3-IN-75 is an orally active NLRP3 inhibitor. NLRP3-IN-75 suppresses IL-1β secretion (IC50 = 23 nM). NLRP3-IN-75 selectively inhibits NLRP3 activation by disrupting inflammasome assembly without affecting NLRC4 or AIM2 inflammasomes. NLRP3-IN-75 exhibits superior efficacy in acute peritonitis, diabetic kidney disease and IBD models .
Cat. No.: HY-P0165B
CAS No.: 1022150-16-8
Synonyms: ITM077 acetate; R1583 acetate; BIM51077 acetate
Target:
Research Areas:
Cat. No.: HY-P5396
CAS No.: 152468-44-5
Target:
Research Areas:
Cat. No.: HY-15195R
CAS No.: 290815-26-8
Synonyms: Ro 67-0565 (Standard); SPP-301 (Standard)
Research Areas:
Avosentan (Standard) is the analytical standard of Avosentan (HY-15195). This product is intended for research and analytical applications. Avosentan is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction, and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.
Cat. No.: HY-120974
CAS No.: 691410-93-2
Target:
Research Areas:
α-Lipoic Acid Derivative 1 (Compound AN-7) is an α-lipoic acid derivative that enhances glucose transport in skeletal muscle by releasing active α-lipoic acid (LA), significantly improving glucose metabolism. In L6 skeletal muscle cells, α-Lipoic Acid Derivative 1 significantly increases glucose transport rates, approximately 12 times more potent than the parent compound α-lipoic acid (HY-N0492). In a mild diabetic mouse model, 10 mg/kg of α-Lipoic Acid Derivative 1 administered for two weeks significantly reduced blood glucose levels by 39%. α-Lipoic Acid Derivative 1 shows significant potential in research related to glucose metabolism in diabetes .
Cat. No.: HY-W017370R
CAS No.: 99-48-9
Cat. No.: HY-W027553S1
Synonyms: NIK-247-d9 free base
Cat. No.: HY-N0259R
CAS No.: 110623-73-9
Synonyms: Epmedin B (Standard)
Cat. No.: HY-123974
CAS No.: 2252478-54-7
Target:
Research Areas:
BR101549 is a non-TZD agonist of PPARγ. BR101549 activates PPARγ to the level of Pioglitazone in vitro. BR101549 can control blood glucose level in mouse model. BR101549 can be studied in anti-diabetic research .
Cat. No.: HY-182438
CAS No.: 91456-99-4
Target:
Research Areas:
SDZ 51641 is an orally active fatty acid oxidation inhibitor. By reducing fatty acid oxidation, SDZ 51641 deprives the gluconeogenesis process of required energy and cofactors, thereby lowering blood glucose levels in diabetic models. SDZ 51641 can be used in diabetes research .
Cat. No.: HY-76383R
CAS No.: 245075-84-7
Target:
Research Areas:
LR-90 (Standard) is the analytical standard of LR-90. This product is intended for research and analytical applications. LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes . LR-90 is also used in the research of diabetic animal model .
Cat. No.: HY-N19615
CAS No.: 134859-90-8
Cat. No.: HY-133806
CAS No.: 912569-37-0
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Fumarranol, a Fumagillin (HY-B0751) analogue, is a selective type 2 methionine aminopeptidase (MetAP2) inhibitor with a human IC50 of 3.2 μM. Fumarranol inhibits proliferation of bovine aortic endothelial cells and inhibits angiogenesis in a mouse matrigel plug model. Fumarranol can be used for the researches of cancer, diabetic retinopathy, age-related macular degeneration .
Cat. No.: HY-181094
Target:
Research Areas:
α-Glucosidase-IN-110 is a selective and orally active competitive inhibitor of α-Glucosidase with an IC50 of 7.09 μM and a Ki of 6.9 μM. α-Glucosidase-IN-110 can reduce fasting blood glucose levels, improve glucose tolerance, and restore the histomorphology of liver and pancreatic tissues in diabetic rat models. α-Glucosidase-IN-110 can be used for the research of diabetes .
Cat. No.: HY-P11584
Target:
Research Areas:
Cat. No.: HY-119058
CAS No.: 463976-07-0
Synonyms: CP-744809
Target:
Research Areas:
ARI-809 (CP-744809) is a highly selective, orally active aldose reductase inhibitor with an IC50 of 1 nM. ARI-809 blocks excessive glucose flux through the polyol pathway. ARI-809 normalizes elevated sorbitol and fructose levels in sciatic nerve tissues of diabetic rat models, inhibits sorbitol accumulation in lens tissues, and brings elevated urinary albumin excretion close to normal. ARI-809 can be used in diabetes research .
Cat. No.: HY-180527
Target:
Research Areas:
SGLT2-IN-5 (Compound 99) is an orally active SGLT2 inhibitor with IC₅₀ values for SGLT2, SGLT1, and DPP4 of 0.8, 23, and 58 nM respectively. SGLT2-IN-5 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-5 can be used for the study of type 2 diabetes .
Cat. No.: HY-180528
Target:
Research Areas:
SGLT2-IN-6 (Compound 101) is an orally active SGLT2 inhibitor with IC₅₀ values for SGLT2, SGLT1, and DPP4 of 0.8, 6.7, and 72 nM respectively. SGLT2-IN-6 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-6 can be used for the study of type 2 diabetes .
Cat. No.: HY-189670
Target:
Research Areas:
α-Glucosidase-IN-126 is a selective and competitive α-glucosidase inhibitor with an IC50 of 0.2 μM and a Ki of 200 nM. α-Glucosidase-IN-126 blocks carbohydrate hydrolysis, inhibits bovine serum albumin glycation, and dose-dependently reduces blood glucose in a diabetic zebrafish model. α-Glucosidase-IN-126 shows minimal cytotoxicity toward normal fibroblasts at low concentrations. α-Glucosidase-IN-126 can be used for research on type 2 diabetes .
Cat. No.: HY-P992410
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
